MagicRNA raises hundreds of millions of yuan in Series B financing to advance world’s first in vivo CAR-T therapy
Recently, Shenzhen MagicRNA Biotechnology Co., Ltd. (or MagicRNA) announced the completion of a Series B financing round of several hundred million yuan. This round was led by a fund under CICC Capital, co-led by Kangjun Capital , with participation from…